Literature DB >> 14513254

[Drug-induced exanthema caused by pegylated interferon-alpha 2b].

S Meller1, A Erhardt, A Auci, N J Neumann, B Homey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14513254     DOI： 10.1007/s00105-003-0600-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


× No keyword cloud information.
  11 in total

1.  Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus.

Authors:  J A Manjón-Haces; F Vázquez-López; S Gómez-Díez; A Hidalgo-García; R Pérez-Alvarez; T Soler-Sánchez; N Pérez-Oliva
Journal:  Acta Derm Venereol       Date:  2001 Jun-Jul       Impact factor: 4.437

2.  A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

Authors:  K L Lindsay; C Trepo; T Heintges; M L Shiffman; S C Gordon; J C Hoefs; E R Schiff; Z D Goodman; M Laughlin; R Yao; J K Albrecht
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

Review 3.  Pegylated interferons.

Authors:  D E Baker
Journal:  Rev Gastroenterol Disord       Date:  2001

4.  Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C.

Authors:  C Taylor; D A Burns; M J Wiselka
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

5.  Interferon-induced sarcoidosis.

Authors:  Ami N Rubinowitz; David P Naidich; Cesar Alinsonorin
Journal:  J Comput Assist Tomogr       Date:  2003 Mar-Apr       Impact factor: 1.826

6.  [Alpha interferon-induced eczema in atopic patients infected by hepatitis C virus: 4 case reports].

Authors:  L Berger; V Descamps; Y Marck; L Dehen; M Grossin; B Crickx; P Marcellin; S Belaich
Journal:  Ann Dermatol Venereol       Date:  2000-01       Impact factor: 0.777

Review 7.  Pegylation: a novel process for modifying pharmacokinetics.

Authors:  J M Harris; N E Martin; M Modi
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients.

Authors:  O Dereure; N Raison-Peyron; D Larrey; F Blanc; J-J Guilhou
Journal:  Br J Dermatol       Date:  2002-12       Impact factor: 9.302

Review 9.  Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.

Authors:  Stephen Youngster; Yu-Sen Wang; Michael Grace; James Bausch; Ronald Bordens; Daniel F Wyss
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

Review 10.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.

Authors:  L M Pfeffer; C A Dinarello; R B Herberman; B R Williams; E C Borden; R Bordens; M R Walter; T L Nagabhushan; P P Trotta; S Pestka
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701
View more
  3 in total

1.  [Sarcoidosis induced by therapy with pegylated interferon alfa-2a].

Authors:  D Bruch-Gerharz; J Reifenberger
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

2.  Resolved heart tamponade and controlled exophthalmos, facial pain and diabetes insipidus due to Erdheim-Chester disease.

Authors:  Jaume Monmany; Esther Granell; Laura López; Pere Domingo
Journal:  BMJ Case Rep       Date:  2018-10-17

3.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.